| Varieties: | General Disease Prevention Medicine |
|---|---|
| Component: | Chemical Synthetic Drugs |
| Type: | The First Class |
| Pharmacodynamic Influential Factors: | Combined Medication |
| Storage Method: | Prevent High or LowTemperature |
| Transport Package: | Color Bags |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier |
Flunixin Meglumine granule antipyretic medicine for animal |
| Main composition : Flunixin Meglumine |
| Character : It is a kind of white or light yellow granule |
|
Pharmacologic action : pharmacodynamics: Flunisine meglumine is a strong cyclooxygenase inhibitor with analgesic, antipyretic, anti - inflammatory and anti - rheumatic effects. Analgesic effect is caused by inhibiting the synthesis of peripheral prostaglandins or their nociceptive sensitizers or their combined action, thereby blocking the conduction of nociceptive impulses. The anti-inflammatory effect of peripheral tissues may be caused by inhibiting cyclooxygenase, reducing the formation of prostaglandin precursors, and inhibiting the local inflammatory response caused by other mediators. Flunisine does not affect gastrointestinal motility in horses but may improve hemodynamics in septic shock animals. pharmacokinetics: After a single intramuscular injection of pigs (2.2mg/kg body weight), the plasma elimination half-life was 3-4 hours, and the peak concentration was 2.94 g/mL, the peak time was 0.4 hours, and the drug could still be detected in the blood after 18 hours of administration. The apparent volume of distribution was 2.0l /kg, and the bioavailability of a single neck injection was 87% Drug interactions: (1) When used in conjunction with other nsaids, the adverse effects on the gastrointestinal tract can be exacerbated, such as Ulcer, bleeding (2) Because of the high binding rate of plasma protein, when combined with other drugs, flunisine meglumine may replace other drugs combined with plasma protein or be itself replaced by other drugs, so that the effect of the drug to be replaced is enhanced, or even produce toxicity |
| Action and use: Antipyretic and analgesic anti-inflammatory drug, one dose, each 1kg bodyweight dog, cat 40mg., 1-2 times a day, Continuous use does not exceed 5 days |
| Precaution: (1)Use with caution in patients with peptic ulcer (2)Do not use together with other nsaids |
| Specification : calculated by C14H11F3N2O2 5% |
| Storage : seal well and keep in dark place |
| Package: 1kg/ 25kg |
| Manufacturer: Jiangxi Bolai Pharmacy Co.,Ltd |
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}